Singular Genomics Systems, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew Spaventa
- Full Time Employees
- 255
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 10931 North Torrey Pines Road La Jolla CA United States of America 92037
- IPO Date
- May 27, 2021
- CIK
- 0001850906
- Website
- singulargenomics.com
- Similar Companies
- Business
- Singular Genomics Systems, Inc. (Nasdaq: OMIC) develops next-generation sequencing (NGS) and spatial multiomics technologies for researchers and clinicians in the life sciences sector; its core products include the commercially available G4 Sequencing Platform, a versatile benchtop sequencer utilizing proprietary four-color sequencing-by-synthesis chemistry for rapid genomic applications, and the G4X Spatial Sequencer, an advanced high-throughput platform enabling in situ transcriptomics, proteomics, fluorescent H&E imaging, and multiomic analysis at subcellular resolution from formalin-fixed paraffin-embedded (FFPE) tissues, complemented by customizable spatial services such as gene panel design up to 500-plex, sample processing, and bioinformatics support for applications in precision diagnostics, drug discovery, and 3D tumor microenvironment studies. Founded in 2016 and headquartered in San Diego, California, the company operates primarily in North America with expanding efforts in Europe and Asia-Pacific, targeting academic research, clinical diagnostics, and translational medicine. In December 2024, Singular Genomics entered a definitive agreement to be acquired by an affiliate of Deerfield Management Company, L.P. for $20.00 per share in cash, a transaction that closed in February 2025, taking the company private to enhance strategic flexibility in advancing its spatial biology platform.
Singular Genomics Announces Closing of Acquisition by Deerfield Management
Investors With Losses Are Invited To Join The Schall Law Firm In An Investigation Into Singular Genomics Systems, Inc. For Securities Fraud
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud
Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
OMIC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Singular Genomics Systems, Inc. Is Fair to Shareholders
SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC
OMIC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Singular Genomics Systems, Inc. Is Fair to Shareholders
Shareholder Alert: Ademi LLP Investigates Whether Singular Genomics Systems, Inc. is Obtaining a Fair Price for Its Public Shareholders